Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Datopotamab-Deruxtecan in Triple-negative Breast Cancer With Brain Metastases
NCT05866432Phase 2Active, not recruiting
- Sponsor
- Medical University of Vienna
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial, sponsored by Medical University of Vienna. Started Jul 2023; status: active, not recruiting.
Beyond the preview
Go deeper on NCT05866432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05866432.